Navigation Links
Novel cytokine protects mice from colitis
Date:8/23/2011

Inflammatory bowel disease (IBD), which affects more than 1 million patients in North America, results from an uncontrolled immune response triggered by environmental factors, such as bacteria, in people genetically predisposed to the disorder. Ulcerative colitis, or inflammation of the lining of the colon, is one such condition.

The aberrant immune response found in IBD is prompted by different cytokines small signaling proteins secreted by various cells, including immune cells that activate the immune system, causing chronic inflammation.

Now researchers led by Jess Rivera-Nieves, MD, of the Inflammatory Bowel Disease Center, Division of Gastroenterology at the University of California, San Diego School of Medicine, have discovered that expression of a newly identified human cytokine Interleukin 37 (IL-37) protects mice from colitis. The study will be published this week in Proceedings of the National Academy of Sciences (PNAS).

IL-37 is a member of the IL-1 family and functions as an inhibitor of innate inflammation and immunity. While most molecules in the IL-1 family appear to promote an inflammatory response, IL-37 modulates or downgrades inflammation.

Charles A. Dinarello, MD, from the University of Colorado, recently expressed human IL-37 in lab mice, which do not have an orthologue, or similar molecule, for this particular cytokine. Nonetheless, IL-37 works the same in both mice and humans. The mice were then fed water containing dextran sulfate sodium (DSS), a substance that induces colitis, to see whether IL-37 provided protection from intestinal inflammation.

It did. "While we still don't understand its mechanism of action, our hope is that, in the future, scientists may be able to engineer cells to overproduce IL-37 and use it to treat or control an overactive immune system in humans," said Rivera-Nieves.

That would represent a major advance in treating IBD, particularly for the 30 to 50 percent of IBD patients for whom highly effective biological therapies tumor necrosis factor inhibitors don't work, or for an even larger percentage of patients whose symptoms eventually return.


'/>"/>

Contact: Debra Kain
ddkain@ucsd.edu
619-543-6163
University of California - San Diego
Source:Eurekalert

Related medicine news :

1. FDA Approves Novel Melanoma Drug
2. St. Michaels North America first to use novel blood-cleaning procedure for kidney transplant
3. Novel DNA sequencer for MDCs systems biology
4. Novel Virus Jumped From Monkeys to Humans, Researchers Find
5. Novel combined therapy extends life, diminishes pain in brain cancer patients
6. Experiment aboard shuttle Atlantis will test novel therapy to build bone during space travel
7. Study uncovers novel genetic variation linked to increased risk of sudden cardiac arrest
8. Novel analysis method organizes genomic cancer data
9. Scientists identify a novel mechanism for evolution of highly aggressive cancers
10. CSHL structural biologists reveal novel drug binding site in NMDA receptor subunit
11. HIV-infected donors present novel source of organs for HIV-infected transplant candidates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can now ... and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings ... The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the ...
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle ... chronic pain and the benefits of holistic treatments, Serenity Recovery Center of ... Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, ... and the Road To Recovery® program to drive cancer patients to and from their ... to ensure the highest quality of life and ongoing independence. Getting to and ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... client, The Grove Investment Group (TGIG), has initiated cultivation and processing operations at ... Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical Systems ... "Company"), which develops, markets and sells medical devices and ... , signed a strategic cooperation agreement with Hongyuan Supply ... Supply Chain") on June 20, 2016, to develop Dehaier,s ... strategic cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s ...
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/23/2016)... Research and Markets has announced the addition of the ... report to their offering. ... failure, it replaces the function of kidneys by removing the ... the treatment helps to keep the patient body,s electrolytes such ... Increasing number of ESRD patients & substantial healthcare expenditure on ...
Breaking Medicine Technology: